|
Cardiovascular Diseases
|
0.500 |
Biomarker
|
group |
BEFREE |
Validation of a Newly Developed Equation for Estimating Serum Apolipoprotein B: Associations with Cardiovascular Disease Surrogate Markers in Koreans.
|
28792141 |
2017 |
|
Cardiovascular Diseases
|
0.500 |
Biomarker
|
group |
BEFREE |
The effect of KJM on new lipid targets of cardiovascular disease (CVD) risk is also unknown.<b>Objective:</b> This systematic review and meta-analysis aimed to assess the effect of KJM on LDL cholesterol, non-HDL cholesterol, and apolipoprotein B.<b>Design:</b> Medline, Embase, CINAHL, and the Cochrane Central databases were searched.
|
28356275 |
2017 |
|
Cardiovascular Diseases
|
0.500 |
GeneticVariation
|
group |
BEFREE |
Apolipoprotein-B (apoB) remnants also contribute to CVD risk and are similarly cleared by the LDLR.
|
28673045 |
2017 |
|
Cardiovascular Diseases
|
0.500 |
GeneticVariation
|
group |
BEFREE |
Cardiovascular disease risk associated with serum apolipoprotein B is modified by serum vitamin A.
|
28774484 |
2017 |
|
Cardiovascular Diseases
|
0.500 |
AlteredExpression
|
group |
BEFREE |
Increased serum triglyceride and apolipoprotein B (apoB) levels and decreased high-density lipoprotein cholesterol (HDL-C) levels are risk factors for cardiovascular diseases.
|
28506386 |
2017 |
|
Cardiovascular Diseases
|
0.500 |
GeneticVariation
|
group |
BEFREE |
This study aims to assess the relationships of total cholesterol (TC), high-density lipoprotein cholesterol (HDL-C), triglycerides (TG), apolipoprotein (a) (apo(a)), apoB-100, and lipoprotein(a) (Lp(a)) with risk of common cancer forms and total cancer mortality in comparison to incidence and mortality of CVD.
|
29254484 |
2017 |
|
Cardiovascular Diseases
|
0.500 |
Biomarker
|
group |
BEFREE |
Prediction of future cardiovascular disease with an equation to estimate apolipoprotein B in patients with high cardiovascular risk: an analysis from the TNT and IDEAL study.
|
28830468 |
2017 |
|
Cardiovascular Diseases
|
0.500 |
GeneticVariation
|
group |
BEFREE |
Homozygous autosomal dominant hypercholesterolaemia (hoADH), an orphan disease caused by mutations in low-density lipoprotein receptor (LDLR), apolipoprotein B (APOB), or proprotein convertase subtilisin-kexin type 9 (PCSK9), is characterized by elevated plasma low-density lipoprotein-cholesterol (LDL-C) levels and high risk for premature cardiovascular disease (CVD).
|
24585268 |
2015 |
|
Cardiovascular Diseases
|
0.500 |
AlteredExpression
|
group |
BEFREE |
Subjects with ≥32 tandem repeats on both HO-1 alleles compared with the rest of the population (recessive trait) featured substantially increased cardiovascular disease risk (hazard ratio [95% confidence interval], 5.45 [2.39, 12.42]; P<0.0001), enhanced atherosclerosis progression (median difference in atherosclerosis score [interquartile range], 2.1 [0.8, 5.6] versus 0.0 [0.0, 2.2] mm; P=0.0012), and a trend toward higher levels of oxidized phospholipids on apolipoprotein B-100 (median oxidized phospholipids/apolipoprotein B level [interquartile range], 11364 [4160, 18330] versus 4844 [3174, 12284] relative light units; P=0.0554).
|
25359861 |
2015 |
|
Cardiovascular Diseases
|
0.500 |
GeneticVariation
|
group |
BEFREE |
We found substantial differences in the effects of the same APOE and APOB alleles on CVD and TC across generations.
|
23320904 |
2013 |
|
Cardiovascular Diseases
|
0.500 |
Biomarker
|
group |
BEFREE |
The extracellular matrix proteoglycan biglycan (BGN) is involved in cardiovascular disease pathophysiology, as it mediates the subendothelial retention of atherogenic apolipoprotein B-containing lipoproteins, affects adaptive remodeling after myocardial infarction, and exerts proinflammatory effects in macrophages.
|
23393390 |
2013 |
|
Cardiovascular Diseases
|
0.500 |
AlteredExpression
|
group |
BEFREE |
The present review examines, with focus on general population studies, apolipoprotein B levels as a predictor of ischemic cardiovascular disease, as well as the association of mutations and polymorphisms in APOB with plasma apolipoprotein B levels, and risk of ischemic cardiovascular disease.
|
19200547 |
2009 |
|
Cardiovascular Diseases
|
0.500 |
Biomarker
|
group |
BEFREE |
Recent data demonstrate that apolipoprotein B (apo B) is a better measure of circulating LDL particle number (LDL-P) concentration and is a more reliable indicator of risk than LDL-C, and there is growing support for the idea that addition of apo B measurement to the routine lipid panel for assessing and monitoring patients at risk for cardiovascular disease (CVD) would enhance patient management.
|
19168552 |
2009 |
|
Cardiovascular Diseases
|
0.500 |
AlteredExpression
|
group |
BEFREE |
Hypertriglyceridemia is an independent risk factor in the development of cardiovascular diseases, and we have previously reported that oral administration of a grape seed procyanidin extract (GSPE) drastically decreases plasma levels of triglycerides (TG) and apolipoprotein B (ApoB) in normolipidemic rats, with a concomitant induction in the hepatic expression of the nuclear receptor small heterodimer partner (NR0B2/SHP).
|
18720348 |
2008 |
|
Cardiovascular Diseases
|
0.500 |
GeneticVariation
|
group |
BEFREE |
The associations between lower levels of autoantibodies against the apo B-100 p45 sequence and cardiovascular disease are in agreement with previous experimental studies demonstrating that these antibodies have atheroprotective effects.
|
17214995 |
2007 |
|
Cardiovascular Diseases
|
0.500 |
Biomarker
|
group |
CTD_human |
Candidate gene polymorphism in cardiovascular disease: the BIP cohort.
|
16544732 |
2006 |
|
Cardiovascular Diseases
|
0.500 |
Biomarker
|
group |
BEFREE |
Familial combined hyperlipidemia (FCH) is characterized by elevated levels of total cholesterol (TC), triglycerides (TG) and apolipoprotein B (apo B) and is associated with premature cardiovascular disease (CVD).
|
16432543 |
2006 |
|
Cardiovascular Diseases
|
0.500 |
Biomarker
|
group |
CTD_human |
This mixed dyslipidemia (or "lipid quartet"): hypertriglyceridemia, low high-density lipoprotein cholesterol levels, a preponderance of small, dense low-density lipoprotein particles and an accumulation of cholesterol-rich remnant particles (e.g. high levels of apolipoprotein B)--emerged as the greatest "competitor" of low-density lipoprotein-cholesterol among lipid risk factors for cardiovascular disease.
|
17002798 |
2006 |
|
Cardiovascular Diseases
|
0.500 |
GeneticVariation
|
group |
BEFREE |
All carriers of an APOB mutation were completely free from CVD.
|
15805152 |
2005 |
|
Cardiovascular Diseases
|
0.500 |
Biomarker
|
group |
BEFREE |
Thus, passive immunization against MDA-modified apoB-100 peptide sequences may represent a novel therapeutic approach for prevention and treatment of cardiovascular disease.
|
15451805 |
2004 |
|
Cardiovascular Diseases
|
0.500 |
GeneticVariation
|
group |
BEFREE |
Other key aspects of lipoprotein metabolism and cardiovascular disease risk such as apolipoprotein B-100, the LDL receptor, apolipoprotein C-III or apolipoprotein (a) will be updated.
|
12589187 |
2003 |
|
Cardiovascular Diseases
|
0.500 |
GeneticVariation
|
group |
BEFREE |
Two hundred and thirty-five patients selected for having severe hypercholesterolaemia and a family history of cardiovascular disease were classified as FH (57 men and 38 women) or non-FH (84 men and 56 women) according to a genetic analysis of the LDL-R or ApoB genes.
|
12492446 |
2003 |
|
Cardiovascular Diseases
|
0.500 |
GeneticVariation
|
group |
BEFREE |
Molecular variation at the apolipoprotein B gene locus in relation to lipids and cardiovascular disease: a systematic meta-analysis.
|
12942366 |
2003 |
|
Cardiovascular Diseases
|
0.500 |
Biomarker
|
group |
BEFREE |
A positive family history for cardiovascular disease also showed a direct and significant correlation to total cholesterol, LDL-cholesterol and apolipoprotein B.
|
10961094 |
2000 |
|
Cardiovascular Diseases
|
0.500 |
Biomarker
|
group |
BEFREE |
Apolipoprotein(B) [apo(B)] reflects the total mass of atherogenic particles (VLDL, IDL, and LDL), and its increase is associated with cardiovascular disease independently of LDL cholesterol (LDLc) levels.
|
10332687 |
1999 |